Veradermics priced an upsized initial public offering.
FEB 4, 2026
Veradermics closed an oversubscribed $150M Series C for Phase 3 hair regrowth trials.
OCT 16, 2025
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company developing innovative therapeutics for pattern hair loss, including the investigational product VDPHL01, which aims to be the first oral, non-hormonal FDA-approved therapy for this condition
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company developing innovative therapeutics for pattern hair loss, including the investigational product VDPHL01, which aims to be the first oral, non-hormonal FDA-approved therapy for this condition.